These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 17343717)
1. Defibrillator therapies in hypertrophic cardiomyopathy: too many swings at bad pitches? Kim SS; Knight BP J Cardiovasc Electrophysiol; 2007 May; 18(5):488-9. PubMed ID: 17343717 [No Abstract] [Full Text] [Related]
4. Implantable cardioverter-defibrillators in patients with Chagas heart disease: misperceptions, many questions and the urgent need for a randomized clinical trial. Rassi A J Cardiovasc Electrophysiol; 2007 Dec; 18(12):1241-3. PubMed ID: 17971129 [No Abstract] [Full Text] [Related]
5. Re: Predictors of all-cause mortality for patients with chronic Chagas' heart disease receiving implantable cardioverter defibrillator therapy. Cardinalli-Neto A; Bestetti RB; Cordeiro JA J Cardiovasc Electrophysiol; 2008 Apr; 19(4):E34-5. PubMed ID: 18298517 [No Abstract] [Full Text] [Related]
6. Clustering of ventricular arrhythmias: a therapeutic opportunity or strictly a marker of poor prognosis? Curtis AB J Cardiovasc Electrophysiol; 2006 Dec; 17(12):1307-9. PubMed ID: 17034407 [No Abstract] [Full Text] [Related]
7. Primary prophylaxis of sudden death in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and dilated cardiomyopathy. Klein GJ; Krahn AD; Skanes AC; Yee R; Gula LJ J Cardiovasc Electrophysiol; 2005 Sep; 16 Suppl 1():S28-34. PubMed ID: 16138882 [TBL] [Abstract][Full Text] [Related]
8. Extensive myocardial fibrosis in a patient with hypertrophic cardiomyopathy and ventricular tachycardia without traditional high-risk features. Bongioanni S; Spirito P; Masi AS; Chiribiri A; Bonamini R; Conte MR Circ Cardiovasc Imaging; 2009 Jul; 2(4):349-50. PubMed ID: 19808616 [No Abstract] [Full Text] [Related]
9. Predictors of syncope in patients with hypertrophic cardiomyopathy. Haghjoo M; Faghfurian B; Taherpour M; Fazelifar AF; Mohammadzadeh S; Alizadeh A; Sadr-Ameli MA Pacing Clin Electrophysiol; 2009 May; 32(5):642-7. PubMed ID: 19422586 [TBL] [Abstract][Full Text] [Related]
10. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death. Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084 [TBL] [Abstract][Full Text] [Related]
11. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692 [TBL] [Abstract][Full Text] [Related]
18. It is time to check estimated glomerular filtration rate level in implantable cardioverter-defibrillator patients. Zareba W Europace; 2009 Nov; 11(11):1415-6. PubMed ID: 19880405 [No Abstract] [Full Text] [Related]
19. Right ventricular pacing is associated with impaired overall survival, but not with an increased incidence of ventricular tachyarrhythmias in routine cardioverter/defibrillator recipients with reservedly programmed pacing. Stockburger M; Celebi O; Krebs A; Knaus T; Nitardy A; Habedank D; Dietz R Europace; 2009 Jul; 11(7):924-30. PubMed ID: 19447808 [TBL] [Abstract][Full Text] [Related]
20. A comprehensive approach to management of ventricular arrhythmias. Kusumoto F Cardiol Clin; 2008 Aug; 26(3):481-96, vii. PubMed ID: 18538192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]